2024
Flourishing Development
——————————————————————
• Complete Series C financing • HPV therapeutic vaccine received grant support from the Bill and Melinda Foundation • Innovative vaccine production platform officially launched
——————————————————————
2020-2023
Strategic Layout
——————————————————————
• The launch ceremony and groundbreaking celebration of the innovative vaccine research and industrialization project of the group company have been successfully concluded.
• Completed billions of yuan in Series A financing, promoting clinical research and industrialization base construction of innovative vaccine projects.
• The domestic first and new technology route - the MAXVAX recombinant rotavirus subunit vaccine project has entered the clinical trial stage. • Establishment of wholly-owned subsidiary - Shanghai Ayk Biotechnology Co., Ltd.
——————————————————————
2018-2020
MAXVAX
——————————————————————
• Establishment of wholly-owned subsidiary - Chengdu Huarenkang Biotechnology Co., Ltd. • Complete Pre-A and Pre-A+rounds of financing • Maikokang Biotechnology was selected as one of the "Top 50 Most Valuable Investment Enterprises in China" on the 2018 New Sprout List
——————————————————————
Phone
+86-21-68403318
QQ
1905311766
WeChet
WeChet
Scan Code
On-Line
Submit